clinical trial · NCT07146191
RE104 Radiolabeled Mass Balance (hAME) Study
Healthy Participant Study2-[14C]-RE104 for Injection
brief summary
The purpose of this study is to characterize the absorption, metabolism and routes of excretion of RE104 and its metabolites in healthy volunteers. This study will quantify drug and metabolites in blood, urine, and feces samples collected before study drug administration and through at least 168 hours after SC dosing of \[14C\]-RE104.
started
Aug 19, 2025
primary completion
Oct 2, 2025
completion
Oct 2, 2025
last updated
Nov 20, 2025
official title
A Phase 1, Open-label, Single Period Study to Evaluate the Absorption, Metabolism, and Excretion of a Single Microdose of [14C]-RE104 in Healthy Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol